Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)

Next Previous
Trial Profile

A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SC 291 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms ARDENT
  • Sponsors Sana Biotechnology

Most Recent Events

  • 06 Nov 2025 According to Sana Biotechnology media release, status changed from active, no longer recruiting to suspended.
  • 06 Nov 2025 According to Sana Biotechnology media release, the company has suspended enrollment and further internal investment in this study to prioritize SC451 and fusogen programs.
  • 11 Nov 2024 Planned End Date changed from 1 Dec 2027 to 4 Nov 2038.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top